C. Kleinbloesem

发表

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men

K. Wesnes, F. Brunner‐Ferber, C. Kleinbloesem, 1996, Clinical pharmacology and therapeutics.

Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure.

J. Wetzels, H. Kloke, F. Huysmans, 1989, British journal of clinical pharmacology.

Quantitative evidence of peripheral conversion of angiotensin within the human leg: effects of local angiotensin-I administration and angiotensin-converting enzyme inhibition on regional blood flow and angiotensin-II balance across the leg

S. Gasic, C. Kleinbloesem, G. Heinz, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

ACE Inhibition with Cilazapril Improves Myocardial Perfusion to the Ischemic Regions During Exercise: A Pilot Study

A. Korn, R. Dudczak, S. Gasic, 1990, Journal of cardiovascular pharmacology.

Angiotensin-Converting Enzyme Inhibitors

W. Kirch, G. Belz, C. Kleinbloesem, 1988 .

The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.

W. Kirch, C. Kleinbloesem, K. Stroemer, 1989, British journal of clinical pharmacology.

Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension.

G. Wolf, K. Erb, G. Belz, 1989, Journal of hypertension.

Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.

C. Cannon, T. Jannett, C. Valcke, 1999, Circulation.

Renin Release Regulation During Acute Renin Inhibition in Normal Volunteers

G. Chatellier, C. Kleinbloesem, P. Bernadet, 1991, Hypertension.

Effect of the Renin Response During Renin Inhibition: Oral Ro 42–5892 in Normal Humans

A. Munafo, E. Camenzind, B. Waeber, 1991, Journal of cardiovascular pharmacology.

Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects

C. Weber, M. Dellenbach, C. Kleinbloesem, 1993, Clinical pharmacology and therapeutics.

Clinical pharmacology of cilazapril.

P. van Brummelen, C. Kleinbloesem, R. Francis, 1989, Drugs.

Anti-D immunoglobulin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels.

A. Halabi, P. Lerch, H. Hustinx, 1998, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Contribution of Splanchnic and Peripheral Vascular Tissues to the Disposal of Angiotensin‐II and to Regional Conversion Rates of Angiotensin‐I: A Pilot Study in Humans

S. Gasic, C. Kleinbloesem, W. Waldhausl, 1991, Journal of cardiovascular pharmacology.

Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

W. Kirch, E. Weidekamm, C. Kleinbloesem, 1998, European Journal of Clinical Pharmacology.

Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.

K. Erb, G. Belz, K. Breithaupt, 1989, British journal of clinical pharmacology.

The Effect of Milk Consumption on the Pharmacokinetics of Fleroxacin and Ciprofloxacin in Healthy Volunteers

C. Kleinbloesem, J. Hoogkamer, 2012, Drugs.

In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: A study of liver and muscle disposition of fleroxacin in humans

I. Gribbestad, T. Skjetne, P. Jynge, 1990, Clinical pharmacology and therapeutics.

Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.

A. Korn, S. Gasic, C. Kleinbloesem, 1989, British journal of clinical pharmacology.

Pharmacokinetic Studies with a Dual-Release Formulation of Levodopa, a Novel Principle in the Treatment of Parkinson’s Disease

J. Dingemanse, C. Crevoisier, C. Kleinbloesem, 1998, European Neurology.

Clinical Pharmacology of Cilazapril

C. Kleinbloesem, P. Brummelen, R. Francis, 2012, Drugs.

Blood Pressure Control by the Renin‐Angiotensin System in Normotensive Subjects: Assessment by Angiotensin Converting Enzyme and Renin Inhibition

F. Bühler, P. van Brummelen, W. Kiowski, 1992, Circulation.

Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

W. Kirch, G. Belz, C. Kleinbloesem, 1988, Clinical pharmacokinetics.

Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.

A. Wellstein, G. Belz, C. Kleinbloesem, 1988, British journal of clinical pharmacology.

Pharmacokinetics and bioavailability of percutaneous ibuprofen.

C. Kleinbloesem, F. Wilkinson, M. Ouwerkerk, 1995, Arzneimittel-Forschung.

PHARMACOKINETICS AND NEPHROTOXICITY OF CYCLOSPORINE IN RENAL TRANSPLANT RECIPIENTS

D. Breimer, L. van Es, L. Paul, 1985, Transplantation.

Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment.

R. Heinig, A. Halabi, J. Dingemanse, 1999, Therapeutic drug monitoring.

Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients.

P. Williams, O. G. Nilsen, O. Sellevold, 1989, British journal of clinical pharmacology.

Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function

W. Kirch, C. Kleinbloesem, J. Hoogkamer, 1997, European Journal of Clinical Pharmacology.

Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure

W. Kirch, C. Kleinbloesem, J. Hoogkamer, 1998, European Journal of Clinical Pharmacology.